Ann: Remplir Gains Australian Reimbursement, page-40

Tend to agree Mm,

Orthocell is a small cap for many, many, many reason, it will continue to remain a small cap for the same reasons without change.
Institutional investment are not interested in supporting a company that makes 5 - 10 million in revenue per year, most retail will sell on highs and buy back in on the low, Orthocell is a small cap.

An Australian partnership for Striate+, TGA approved to sell only in Australia saw a 2% increase sold down 5% by the end of the days trade. One year later a global partnership TGA, FDA approved Striate + saw a 23% increase in share price, 23 million extra in the bank with our first sales recorded this quarter.

An Australian partnership for Remplir, TGA approved to sell in Australia & NZ saw maybe 2-3% gains, it hasnt been sold down yet, do you see where im going with this, FDA approved, global partnership 80 million in the bank, first sales a few months after that.

The same will happen to Ortho-ATI, could be next year, or the year after that.

The same with Orth-ACL ( rope ) a long way off but if its as good as they say, our REVENUE will increase ten fold.

Eight years Ive been waiting for this turd ( tide to change ) , looks like Ill have to wait a little longer.

I would recommend a shares buy back scheme when Remplir is under a global partnership, market price of $1.20, no less, any share holder with less than 10 thousand, seems a no brainer. We got to start fighting with the big boys than, this move will save us from getting bought out, cheaply.